Clinical trials
Cardiomyopathy, Dilated trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Unknown status | 3 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ethicare GmbH | 2 |
| Alexion Pharmaceuticals, Inc. | 1 |
| Ancora Heart, Inc. | 1 |
| AstraZeneca | 1 |
| Bristol-Myers Squibb | 1 |
| Institut National de la Santé Et de la Recherche Médicale, France | 1 |
| Leiden University Medical Center | 1 |
| LoneStar Heart, Inc. | 1 |
| Maastricht University Medical Center | 1 |
| Pfizer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiomyopathy, Dilated | 13 |
| Heart Failure | 7 |
| Cardiomyopathies | 4 |
| Arrhythmias, Cardiac | 1 |
| Cognitive Dysfunction | 1 |
| Coronary Artery Disease | 1 |
| Death, Sudden, Cardiac | 1 |
| Diabetes Mellitus | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Heart Defects, Congenital | 1 |
Trials
Showing 26 to 13 of 13. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.